A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of oral 882C87 in immunocompromised patients.
Condition or disease
Drug: NetivudineDrug: Acyclovir
Patients are randomized to receive either 882C87 or acyclovir with corresponding placebos for 14 days, with two hundred patients in each of the two groups. They are stratified by presence or absence of HIV infection. Patients undergo 6 months of follow-up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Acute localized herpes zoster or rash present less than 72 hours, verified by clinical diagnosis.
Immunocompromised condition primarily as a result of documented HIV infection, malignancy, chemotherapy or radiation therapy, solid organ or bone marrow transplant, or chronic immunosuppressive therapy.
Life expectancy of at least 6 months.
Ability to cooperate with the requirements of the study.
Patients with the following symptoms or conditions are excluded:
Evidence of cutaneous or visceral dissemination (more than 20 discrete lesions outside adjacent dermatomes).
Acute, life-threatening condition.
Significant malabsorption syndrome or other gastrointestinal dysfunction that may severely reduce drug absorption.
Intolerance of oral medication.
Tricyclic antidepressants or anti-epileptics.
Topical applications to the zoster lesions that would obscure evaluation.
Fluorouracil and flucytosine.
Systemic therapy with agents with antiherpetic activity (from 2 weeks prior to first dose to day 28 of study).
Probenecid or other drugs likely to affect elimination of study drugs (from 2 days prior to first dose to day 14 of the study).
Warfarin (Coumadin) during 14 days of treatment.
Patients with the following prior conditions are excluded:
History of intolerance, hypersensitivity, or severe drug reaction to acyclovir.
Systemic therapy with agents with antiherpetic activity (including interferon) within the past 2 weeks.
Probenecid or other drugs likely to affect the elimination of 882C87 or acyclovir within the past 48 hours.
Drugs likely to interact with 882C87 (e.g., fluorouracil or flucytosine) within the past 7 days.
Zoster immune globulin or zoster immune plasma within the previous month. History of alcohol or drug abuse within the previous 6 months or current methadone therapy.